Bitcoin, Blockchain & Cryptocurrency News

Bitcoin
%
Ripple
%
Ethereum
%
Show details
Hide details
Market Cap
Volume (24h)
Market Cap
Volume (24h)
Market Cap
Volume (24h)
Starts in 00 days 00 hours
»

Embleema | RWE

Embleema’s blockchain network offers a novel way to put patients at the center of clinical research by letting them own their health data, disrupting the slow, costly, manual and opaque process by which low quality health data is currently collected by pharmaceutical companies through Contrat Research Organisation, to monitor the efficacy of new investigational drugs. Connecting patients directly to medical research and incentivizing them to share their data with tokens, blockchain is the decentralized technology everyone was waiting for to move away from the current linear process of drug approvals, to a new iterative model where trustworthy digital health data is shared in real time between patients, life sciences and regulators. The 21st Century Cures Act (2016) gave the FDA a mandate to accelerate approvals if more patient real world data was shared proactively by pharma. Embleema’s blockchain speeds up this process with patient buy-in, accelerating time to market new drugs.

# Video

# ICO Review


ICO Overview:

  • Symbol: RWE
  • ICO Soft Cap: $2,000,000
  • ICO Hard Cap: $30,000,000
  • Sale opening date: 10 Oct 2019
  • Sale closing date: 1 Jan 2020
  • Blockchain: Ethereum

Team:

France

Robert Chu - CEO and CTO, former head of IMS / IQVIA in France & China, SVP of Technology Solutions

Alexis Normand - Head of Embleema Consortium, former Head of B2B Nokia Digital health /

Pradeep Sreekanthan - Chief Delivery Officer, Former Director at IMS Health

Join our telegram channel